HemaQuest Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.hemaquest.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Effects of HQK-1001 in Patients With Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01601340
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸Children's Hospital and Research Center - Oakland, Oakland, California, United States
🇺🇸Children's National Hospital, Washington, District of Columbia, United States
A Study of HQK-1001 in Patients With Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01322269
- Locations
- 🇺🇸
Children's Hospital and Research Center - Oakland, Oakland, California, United States
🇺🇸University of Miami Miller School of Medicine - Dept of Pediatrics, Miami, Florida, United States
🇺🇸Georgia Health Sciences University - Adult SIckle Cell Center, Augusta, Georgia, United States
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
- Conditions
- Lymphoid MalignanciesLymphoproliferative Disorders
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00992732
- Locations
- 🇺🇸
LPCH/Stanford, Palo Alto, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
- Conditions
- EBV LymphomasLympho-proliferative Diseases
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00917826
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00842088
- Locations
- 🇺🇸
Trialogic Research, Madison, Alabama, United States
🇺🇸Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Century Clinical Research, Inc., Daytona Beach, Florida, United States
- Prev
- 1
- 2
- Next